Pravastatin and cognitive function in the elderly. Results of the PROSPER study

Deutsche Zeitschrift für Nervenheilkunde - Tập 257 - Trang 85-90 - 2009
Stella Trompet1,2, Peter van Vliet1, Anton J. M. de Craen1, Jelle Jolles3, Brendan M. Buckley4, Michael B. Murphy4, Ian Ford5, Peter W. Macfarlane6, Naveed Sattar7, Chris J. Packard8, David J. Stott9, Jim Shepherd8, Eduard L. E. M. Bollen10, Gerard J. Blauw1, J. Wouter Jukema2,11, Rudi G. J. Westendorp1,12
1Department of Gerontology and Geriatrics, C-2-R, Leiden University Medical Center, Leiden, The Netherlands
2Department of Cardiology, Leiden University Medical Centre, Leiden, The Netherlands
3Department of Special Education, Faculty of Psychology and Education, VU University Amsterdam, Amsterdam, The Netherlands
4Department of Pharmacology and Therapeutics, Cork University Hospital, Cork, Ireland
5Robertson Centre for Biostatistics, University of Glasgow, Glasgow, Scotland
6Division of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, Scotland
7BHF Glasgow Cardiovascular Research Centre, Faculty of Medicine, University of Glasgow, Glasgow, Scotland
8Department of Vascular Biochemistry, University of Glasgow, Glasgow, Scotland
9Department of Geriatric Medicine, University of Glasgow, Glasgow, Scotland
10Department of Neurology, Leiden University Medical Centre, Leiden, The Netherlands
11Durrer Center for Cardiogenetic Research, Interuniversity Cardiology Institute, Amsterdam, The Netherlands
12Netherlands Consortium for Healthy Ageing, Leiden, The Netherlands

Tóm tắt

Observational studies have given conflicting results about the effect of statins in preventing dementia and cognitive decline. Moreover, observational studies are subject to prescription bias, making it hard to draw definite conclusions from them. Randomized controlled trials are therefore the preferred study design to investigate the association between statins and cognition. Here we present detailed cognitive outcomes from the randomized placebo-controlled PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). Cognitive function was assessed repeatedly in all 5,804 PROSPER participants at six different time points during the study using four neuropsychological performance tests. After a mean follow-up period of 42 months, no difference in cognitive decline at any of the cognitive domains was found in subjects treated with pravastatin compared to placebo (all p > 0.05). Pravastatin treatment in old age did not affect cognitive decline during a 3 year follow-up period. Employing statin therapy in the elderly in an attempt to prevent cognitive decline therefore seems to be futile.

Tài liệu tham khảo

Neuropathology Group of the Medical Research Council Cognitive Function, Ageing Study (MRC CFAS) (2001) Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Lancet 357:169–175

Heart Protection Study Collaborative Group (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360:7–22

(2008) Late-breaking science abstracts. Neurology 71:153–156

(2009) Cholesterol lowering agent to slow progression of Alzheimer’s disease study (CLASP). http://clinicaltrials.gov/ct2/show/NCT00053599, assessed at 13 July 2009

Cramer C, Haan MN, Galea S, Langa KM, Kalbfleisch JD (2008) Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study. Neurology 71:344–350

Gueorguieva R, Krystal JH (2004) Move over ANOVA: progress in analyzing repeated-measures data and its reflection in papers published in the Archives of General Psychiatry. Arch Gen Psychiatry 61:310–317

Houx PJ, Shepherd J, Blauw GJ, Murphy MB, Ford I, Bollen EL, Buckley B, Stott DJ, Jukema W, Hyland M, Gaw A, Norrie J, Kamper AM, Perry IJ, MacFarlane PW, Meinders AE, Sweeney BJ, Packard CJ, Twomey C, Cobbe SM, Westendorp RG (2002) Testing cognitive function in elderly populations: the PROSPER study. PROspective Study of Pravastatin in the Elderly at Risk. J Neurol Neurosurg Psychiatry 73:385–389

Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K, Soininen H, Tuomilehto J, Nissinen A (2001) Midlife vascular risk factors and Alzheimer’s disease in later life: longitudinal, population based study. BMJ 322:1447–1451

Kuo YM, Emmerling MR, Bisgaier CL, Essenburg AD, Lampert HC, Drumm D, Roher AE (1998) Elevated low-density lipoprotein in Alzheimer’s disease correlates with brain abeta 1–42 levels. Biochem Biophys Res Commun 252:711–715

Okamura N, Arai H, Maruyama M, Matsui T, Tanji H, Sasaki H, Yoshida H, Sugita M (2001) Serum cholesterol and cerebrospinal fluid amyloid beta protein in Alzheimer’s disease. J Am Geriatr Soc 49:1738–1739

Peters R, Beckett N, Forette F, Tuomilehto J, Clarke R, Ritchie C, Waldman A, Walton I, Poulter R, Ma S, Comsa M, Burch L, Fletcher A, Bulpitt C (2008) Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurol 7:683–689

Rockwood K, Kirkland S, Hogan DB, MacKnight C, Merry H, Verreault R, Wolfson C, McDowell I (2002) Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol 59:223–227

Scarpini E, Galimberti D (2009) Alzheimer’s disease: from pathogenesis to novel therapeutic approaches. Therapy 6:259–277

Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, MacFarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG (2002) Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360:1623–1630

Shepherd J, Blauw GJ, Murphy MB, Cobbe SM, Bollen EL, Buckley BM, Ford I, Jukema JW, Hyland M, Gaw A, Lagaay AM, Perry IJ, MacFarlane PW, Meinders AE, Sweeney BJ, Packard CJ, Westendorp RG, Twomey C, Stott DJ (1999) The design of a prospective study of Pravastatin in the Elderly at Risk (PROSPER). PROSPER Study Group. PROspective Study of Pravastatin in the Elderly at Risk. Am J Cardiol 84:1192–1197

Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR (1997) Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA 277:813–817

van Vliet P, van de Water W, de Craen AJ, Westendorp RG (2009) The influence of age on the association between cholesterol and cognitive function. Exp Gerontol 44:112–122

Wolozin B, Wang SW, Li NC, Lee A, Lee TA, Kazis LE (2007) Simvastatin is associated with a reduced incidence of dementia and Parkinson’s disease. BMC Med 5:20

Zandi PP, Sparks DL, Khachaturian AS, Tschanz J, Norton M, Steinberg M, Welsh-Bohmer KA, Breitner JC (2005) Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. Arch Gen Psychiatry 62:217–224

Thông tin
Thông tin xuất bản

Deutsche Zeitschrift für Nervenheilkunde

Tập 257

85-90

Thông tin tác giả